Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China-Reference-Cited by-同舟云学术

Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China

Published:2020-11 Issue:11 Volume:42 Page:2159-2170.e6
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Rui Mingjun^ORCID,Li Hongchao^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. Epidemiology of lung cancer;Alberg;Chest,2003

2. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol,2017

3. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data;William;Chest,2009

4. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study;Han;Lung Cancer,2017

5. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies;Yu;Cancer Res,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of Kang Ai injection plus chemotherapy vs. Shenqi Fuzheng injection plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer;Frontiers in Medicine;2024-05-01

2. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024

3. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

4. Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study;Future Oncology;2023-08

5. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis;Frontiers in Pharmacology;2023-03-20